Oryzon Genomics announced that Roger Bullock has been appointed Chief Medical Officer. Recently he has been working as a consultant for companies active in the CNS space, including Lilly and Merck. With the addition of Dr. Bullock, Dr. César Molinero will transition from his current dual position as Chief Medical and Clinical Operations Officer to concentrate on the role of Chief Clinical Officer. The medical department of the company will further enhance its capabilities with the incorporation of additional clinical research associates. In his new capacity, Dr. Bullock will be responsible for executing the clinical development plan of the epigenetic drugs developed by the company, notably ORY-2001, an oral dual LSD1-MAOB inhibitor currently finishing Phase I in healthy volunteers.